Published in Mol Cell Biol on August 02, 2010
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia (2012) 0.99
HoxA10 protein regulates transcription of gene encoding fibroblast growth factor 2 (FGF2) in myeloid cells. J Biol Chem (2012) 0.89
Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr-abl oncogene. Leuk Lymphoma (2012) 0.86
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med (2013) 0.85
Fas-associated phosphatase 1 (Fap1) influences βcatenin activity in myeloid progenitor cells expressing the Bcr-abl oncogene. J Biol Chem (2013) 0.82
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem (2014) 0.82
The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp). J Biol Chem (2012) 0.82
The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia. Leukemia (2016) 0.81
Growth arrest specific 2 is up-regulated in chronic myeloid leukemia cells and required for their growth. PLoS One (2014) 0.80
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. PLoS One (2013) 0.79
Increased Fanconi C expression contributes to the emergency granulopoiesis response. J Clin Invest (2013) 0.79
The Interferon Consensus Sequence Binding Protein (Icsbp/Irf8) Is Required for Termination of Emergency Granulopoiesis. J Biol Chem (2015) 0.76
Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain. Oncotarget (2016) 0.75
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. PLoS One (2015) 0.75
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia (2015) 0.75
Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes. Oncotarget (2017) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell (2007) 6.07
Genes specifically expressed at growth arrest of mammalian cells. Cell (1988) 5.61
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol (2004) 3.25
Probing chromatin immunoprecipitates with CpG-island microarrays to identify genomic sites occupied by DNA-binding proteins. Methods Enzymol (2003) 2.12
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J (2007) 2.11
Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions. J Immunol (1980) 2.06
Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol (1993) 2.02
The phagosomal proteome in interferon-gamma-activated macrophages. Immunity (2009) 1.95
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood (1998) 1.80
Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem (1997) 1.70
Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia (2006) 1.58
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A (2002) 1.57
PU.1, interferon regulatory factor 1, and interferon consensus sequence-binding protein cooperate to increase gp91(phox) expression. J Biol Chem (1998) 1.41
Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest (2008) 1.33
The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem (2004) 1.29
Constitutively active beta-catenin promotes expansion of multipotent hematopoietic progenitors in culture. J Immunol (2006) 1.28
The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem (2008) 1.13
Biochemical responses in activated human neutrophils mediated by protein kinase C and a Ca2+-requiring proteinase. J Biol Chem (1986) 1.09
Constitutive apoptosis in human neutrophils requires synergy between calpains and the proteasome downstream of caspases. J Biol Chem (1998) 1.09
Recruitment of CREB-binding protein by PU.1, IFN-regulatory factor-1, and the IFN consensus sequence-binding protein is necessary for IFN-gamma-induced p67phox and gp91phox expression. J Immunol (1999) 1.09
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res (2004) 1.08
Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein. Mol Cell Biol (2006) 1.07
Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol (2002) 1.03
The calpain system is involved in the constitutive regulation of beta-catenin signaling functions. J Biol Chem (2005) 1.01
The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J (2001) 0.96
Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia. Leukemia (2004) 0.92
The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation. J Biol Chem (2009) 0.86
Calcium dependent cysteine proteinase is a precursor of a chemotactic factor for neutrophils. Biochem Biophys Res Commun (1989) 0.83
Identification of genes potentially involved in disease transformation of CML. Leukemia (2005) 0.83
Mechanism of differential inhibition of factor-dependent cell proliferation by transforming growth factor-beta 1: selective uncoupling of FMS from MYC. Blood (1993) 0.81
Synergism between stem cell factor and granulocyte-macrophage colony-stimulating factor on cell proliferation by induction of cyclins. Cytokine (2002) 0.81
The role of calpain and protein kinase C in activation of human neutrophils. Prog Clin Biol Res (1988) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Structure of the novel ternary hydrides Li4Tt2D (Tt=Si and Ge). Acta Crystallogr B (2007) 10.58
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci (2005) 3.22
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
Synthesis and anticancer activity of thiosemicarbazones. Bioorg Med Chem Lett (2006) 2.78
Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol (2007) 2.38
Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med (2002) 2.34
Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med (2007) 2.31
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
TARP subtypes differentially and dose-dependently control synaptic AMPA receptor gating. Neuron (2007) 2.07
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol (2005) 1.97
Arrowsmith two-node search interface: a tutorial on finding meaningful links between two disparate sets of articles in MEDLINE. Comput Methods Programs Biomed (2009) 1.96
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.94
Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm (2012) 1.93
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med (2005) 1.84
Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A (2008) 1.81
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72
Genomic and proteomic analyses of the fungus Arthrobotrys oligospora provide insights into nematode-trap formation. PLoS Pathog (2011) 1.72
Inhibitor kappaB-alpha haplotype GTC is associated with susceptibility to acute respiratory distress syndrome in Caucasians. Crit Care Med (2007) 1.71
Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem (2001) 1.71
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Mitomycin C-polyethylene glycol controlled-release film inhibits collagen secretion and induces apoptosis of fibroblasts in the early wound of a postlaminectomy rat model. Spine J (2010) 1.69
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Macroscopic, neat, single-walled carbon nanotube fibers. Science (2004) 1.67
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res (2006) 1.67
AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther (2010) 1.66
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
The impact of the National Essential Medicines Policy on prescribing behaviours in primary care facilities in Hubei province of China. Health Policy Plan (2012) 1.63
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet (2008) 1.62
New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors. J Neurosci (2007) 1.62
HIV prevalence and sexual risk behaviors among men who have sex with men: results from a statewide population-based survey in California. J Acquir Immune Defic Syndr (2006) 1.61
Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56
ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther (2012) 1.55
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev (2002) 1.54
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma (2009) 1.53
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost (2013) 1.53
Jak family of kinases in cancer. Cancer Metastasis Rev (2003) 1.52
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development (2009) 1.50
Electric power and synthesis gas co-generation from methane with zero waste gas emission. Angew Chem Int Ed Engl (2011) 1.49
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2002) 1.47
Anne O'Tate: A tool to support user-driven summarization, drill-down and browsing of PubMed search results. J Biomed Discov Collab (2008) 1.46
Mapping the C. elegans noncoding transcriptome with a whole-genome tiling microarray. Genome Res (2007) 1.46
Heptamethine cyanine dyes with a large stokes shift and strong fluorescence: a paradigm for excited-state intramolecular charge transfer. J Am Chem Soc (2005) 1.45
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Preclinical evaluation of potential nilotinib cardiotoxicity. Leuk Res (2010) 1.43
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.42
Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol (2002) 1.41
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem (2006) 1.41
What is the learning curve for carotid artery stenting with neuroprotection? Analysis of 200 consecutive cases at an academic institution. Perspect Vasc Surg Endovasc Ther (2005) 1.41
Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res (2005) 1.40
The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke (2009) 1.38
The microtubule plus-end tracking protein EB1 is required for Kv1 voltage-gated K+ channel axonal targeting. Neuron (2006) 1.37
True solutions of single-walled carbon nanotubes for assembly into macroscopic materials. Nat Nanotechnol (2009) 1.37
Monitoring of fetal radiation exposure during pregnancy. J Vasc Surg (2013) 1.37
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood (2009) 1.36
Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem (2003) 1.36
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res (2005) 1.36
Dividing glial cells maintain differentiated properties including complex morphology and functional synapses. Proc Natl Acad Sci U S A (2008) 1.36
An mRNA-rRNA base-pairing mechanism for translation initiation in eukaryotes. Nat Struct Mol Biol (2005) 1.35
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2006) 1.34
Statins in tumor suppression. Cancer Lett (2008) 1.34
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis (2005) 1.33
Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest (2008) 1.33
Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene (2002) 1.32
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res (2006) 1.31
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
Surveillance for Creutzfeldt-Jakob disease in China from 2006 to 2007. BMC Public Health (2008) 1.30
The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol (2006) 1.30
The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30
2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther (2008) 1.29
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem (2004) 1.29
Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther (2008) 1.28
LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res (2008) 1.28
Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol (2009) 1.27
A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One (2012) 1.27
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood (2013) 1.26
Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26
The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res (2008) 1.26
The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer (2007) 1.26